Biotech Stocks Facing FDA Decision In February 2025
February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...
FDA approves Vertex's first-in-class non-opioid analgesic for acute pain
Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) Journavx (suzetrigine) 50 milligram oral tablets. This new drug is a non-opioid ...
Here’s Why Immunovant, Inc. (IMVT) Will Double in 2025
We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...
Vertex Pharmaceuticals’ non-opioid Journavx approved for pain by FDA
Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class ...
Vertex gets FDA approval for non-opioid pain reliever
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) rose 3% in post-market trading Thursday on news the company had received FDA ...
Vertex Pharmaceuticals announces FDA approval of Journavx
Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration has approved JOURNAVX, an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor ...
Journey Medical Corporation: Emrosi's Launch Could Be A Turning Point
Journey Medical's future hinges on Emrosi, a new formulation of minocycline for rosacea, showing superior efficacy. Read why ...
Hosted on MSN11h
Is Tonix Pharmaceuticals the Next Biotech Breakout?
Clinical-stage biopharmaceutical company Tonix Pharmaceuticals (NASDAQ: TNXP) is gaining significant attention from investors and market participants. The company develops therapies for conditions ...
First New Non-Opioid Painkiller in Decades Gets FDA Approval
Vertex Pharmaceuticals won U.S. approval for the first new non-opioid painkiller in decades, which could be a blockbuster if the company can persuade insurers and doctors to embrace the non-addictive ...
Chimerix stock soars to 52-week high, hits $4.22
Chimerix Inc (NASDAQ: NASDAQ:CMRX) stock has reached a new 52-week high, touching $4.22 in recent trading, giving the company a market capitalization of $375 million. According to InvestingPro data, ...
Regeneron's SWOT analysis: stock faces eylea challenges amid pipeline promise
Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...
Benzinga.com18h
X4 Pharmaceuticals (NASDAQ:XFOR) Stock Quotes, Forecast and News Summary
FDA Approves X4 Pharmaceuticals' Mavorixafor ... Vandana Singh Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of bluebird bio, Inc ...